Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: Potential benefits and COX-2 as the common mediator in pain, toxicities and survival?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 3, 2006, Pages 232-239

  Lin, Edward H ^a   Curley, Steven A ^a   Crane, Christopher C ^a   Feig, Barry ^a   Skibber, John ^a   Delcos, Marc ^a   Vadhan, Saroj Raj ^a   Morris, Jeffrey ^a   Ayers, Gregory D ^a   Ross, Alicia ^a   Brown, Thomas ^a   Rodriguez Bigas, Miguel A ^a   Janjan, Nora ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Capecitabine; Celecoxib; Hand foot syndrome; Metastatic colorectal cancer; Radiation

Indexed keywords

CAPECITABINE; CELECOXIB; CREATININE; CYCLOOXYGENASE 2; ENDOSTATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; THROMBOSPONDIN 1; THROMBOXANE A2; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; AGITATION; ARTICLE; CANCER GRADING; CANCER GROWTH; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROTOXICITY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PAIN; RADIATION RESPONSE; RASH; SYNCOPE; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLORECTAL TUMOR; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33744975683     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000217818.07962.67     Document Type: Article

References (47)

1. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047.
3. Goldberg RM, Sargent DJ, Morton RF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
4. Tournigand C, Andre T, Achille E. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
5. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059-2069.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
7. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol. 2005;23:16s (Abstr 2).
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
9. Díaz Rubio E, Tabernero J, van Cutsem E. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. Proc Am Soc Clin Oncol. 2005;23:16s (Abstr 3535).
10. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349-358.
11. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
12. Van Cutsem E, Twelves C, Cassidy J. Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
13. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;9:2282-2292.
14. Patt YZ, Liebmann J, Diamandidis D, et al. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): final safety findings from a phase II trial. Proc Am Soc Clin Oncol. 2004;22:15s (Abstr 3602).
15. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084-2091.
16. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol. 1998;16:3537-3541.
17. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest. 2002;20:3-10.
18. Nagore E, Insa A, Sanmartin O, et al. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225-234.
19. Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for Palmar-Plantar erythrodysethesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 1990;8:57-63.
20. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology. 2002;16s:31-37.
21. Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Sem Oncol. 2002;29:111-119.
22. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999;282:1254-1257.
23. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology. 2001;121:1339-1347.
24. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-1311.
25. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362-366.
26. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis. Am J Clin Oncol. 2003;26:S66-S69.
27. Hoff PM, Pazdur R, Lassere Y, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol. 2004;22:2078-2083.
28. Lee JJ, Kim TM, Yu SJ, et al. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil and leucovorin chemotherapy. Jpn J Clin Oncol. 2004;34:400-404.
29. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825.
30. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-1214.
31. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210-2218.
32. Janjan NA, Crane CN, Feig BW, et al. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-FU for locally advanced rectal cancer. Int J Radiation Biol Phys. 2000;47:713-718.
33. Lin E, Skibber J, Delcos M, et al. Phase II study of capecitabine and radiation plus concomitant boost in the treatment of locally advanced rectal cancer: mature report. Proc Am Soc Clin Oncol. 2005;23:269 (Abstr 3593).
34. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II Trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739-8747.
35. Blanquicett C, Saif MW, Buchsbaum DJ, et al. Antitumor efficacy of Capecitabine and Celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res. 2005;11:8773-8781.
36. Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer. 2003;105:868-872.
37. El-Rayes BF, Zalupski M, Shields AF, et al. A Phase II Trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2005;23:308 (Abstr 3677).
38. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005;23:380 (Abstr 4510).
39. Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol. 2005;23:308 (Abstr 4000).
40. Mercer SJ, Di Nicolantonio F, Knight LA, et al. Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors. Anticancer Drugs. 2005;16:495-500.
41. Altorki NK, Port JL, Zhang F, et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res. 2005;11:4191-4197.
42. Topol EJ. Arthritis medicines and cardiovascular events: house of coxibs. JAMA. 2005;293:366-368.
43. Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal Disease. J Am Soc Nephrol. 2002;13:806-816.
44. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci USA. 2002;99:13243-13247.
45. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastro. 2000;95:1681-169.
46. Solomon SD, McMurray JV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
47. Hobson B, Denekamp J. Endothelial proliferation in tumors and normal tissues: continuous labeling studies. Br J Cancer. 1984;49:405-13.